Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarclo Regulatory News (CAR)

Share Price Information for Carclo (CAR)

Share Price is delayed by 15 minutes
Get Live Data
36.60    0.10 (0.27%)
Bid:
36.50
Ask:
36.70
Spread: 0.20 (0.548%)
Market Cap: £26.87m
CAR Live PriceLast checked at - London Stock Exchange

Intraday Carclo Share Chart

Trading Statement

14 Apr 2023 07:00

RNS Number : 1808W
Carclo plc
14 April 2023
 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU NO. 596/2014) WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN

 

14 April 2023

 

Carclo plc

 

("Carclo" or the "Group")

 

Full Year Trading Update

 

Carclo, a preferred and trusted partner of global customers, providing high-precision critical components to the life sciences, aerospace, optics, and technology industries, today provides an update on trading for the financial year ended 31 March 2023 ("FY 2023").

During FY 2023, the Company encountered multiple significant challenges, including the dissolution of a major manufacturing contract, the adverse effects of rising input costs on margins, and increasing interest rates. In response to this altered landscape, the Board shifted the Group's strategy to focus on operational excellence and cash generation. Although the final quarter of FY 2023 has shown early signs of the new strategy's benefits, the overall full-year profit performance is anticipated to be below the previous year. As a result of the new focus on cash generation, the Group expects to deliver an improvement in net debt compared to the position at the half year, whilst having continued to make significant pension deficit repair contributions. The suppressed Manufacturing Solutions margins and reduced Design & Engineering activity within our Carclo Technical Plastics (CTP) business have only been partially counterbalanced by increased manufacturing volumes in CTP and a robust performance from our Aerospace division.

Redefined Strategy

During the latter half of FY2023 it became clear that the cash-intensive top-line growth strategy was unsustainable in the current economic climate. As a result, the Board has refocused the Group's strategy on margin expansion through operational excellence and balance sheet strengthening via cash generation. Our investment priorities now lie in supporting existing projects and continuous improvement with a swift return on investment. While we have already begun implementing this new strategy and there is still much to accomplish, we are witnessing early positive indications of enhanced margins and cash generation as FY2023 concludes.

 

Banking Arrangements

The Board continues to work with its lending bank, HSBC, to ensure that there is appropriate ongoing financial support for the business as it implements the new strategy. HSBC remain supportive and the Group successfully reached an agreement with them to reset the interest cover covenant for 31 March 2023. Discussions are continuing with HSBC regarding the setting of appropriate covenants for the forthcoming financial year.

 

Carclo Technical Plastics (CTP)

The CTP division achieved a robust revenue performance, despite facing significant headwinds during the year. Activity in the Design & Engineering segment reduced from the very high level of the prior year, but remained above historical norms. The Manufacturing Solutions segment delivered significant revenue growth, primarily from our existing customers in the life sciences sector, demonstrating our ability to grow organically in our chosen markets.

 

However, significant margin challenges offset this revenue growth, particularly the unprecedented increase in input costs, including soaring energy prices. While we have been able to pass on some of the higher costs to customers, the time delay in doing so has caused a significant drop in operating margins during the year. The effect of the lower margins was only partially mitigated by increased manufacturing volumes and we therefore expect the divisional underlying operating profit to be materially lower than the prior year.

 

We previously announced the dissolution of a significant manufacturing contract and are engaged in ongoing discussions with the customer to reach a commercial agreement for this contract.

 

Our current focus is on margin recovery through operational efficiency and optimisation. We have begun our factory specialisation journey in the EMEA region, with our UK facility concentrating on long production runs and our Czech facility focusing on short and medium-run products, prioritising flexibility and rapid changeovers. We are now implementing this factory specialisation strategy in the US. Our Chinese and Indian operations demonstrate strong growth potential and enhance our global presence. We expect a steady recovery in operating margins in the near term as our new strategy starts to yield results.

 

Aerospace

Our Aerospace division is witnessing a robust recovery as the aviation industry rebounds, with sales approaching pre-COVID levels. The division's unique market position ensures margin resilience amid inflation, and we expect solid profits and operating cash flow for FY2023. Our focus lies in expanding sales within existing markets and creating high-precision, safety-critical solutions for specialised sectors.

 

Governance

The Board is dedicated to maintaining high governance standards and regulatory compliance. We have restructured the Board, separating the roles of Non-Executive Chairman and Chief Executive, in line with the Corporate Governance Code. Rachel Amey's recent appointment as a Non-Executive Director strengthens the Board, as her financial expertise will help ensure adherence to best practice in financial controls and governance.

 

Outlook

We remain dedicated to providing sustainable earnings growth and value creation for our stakeholders, despite the persistent challenges caused by inflationary pressures. Our new strategy emphasises cash generation, stability, operational excellence, and optimising our global footprint. We are implementing measures to enhance manufacturing and supply chain efficiency while minimising environmental impact. Our endeavours to optimise our global footprint will enable us to serve our customers better, support growth in key markets, and improve financial performance. We expect the business to deliver a substantially improved performance over the medium term as our focus shifts to enhancing margins and return on capital.

 

 

 

About Carclo plc

Carclo plc is a public company whose shares are quoted on the Main Market of the London Stock Exchange. The Group is a preferred and trusted partner of global customers, offering high-precision critical components that meet the needs of life sciences, aerospace, optics, and technology industries.

 

LEI: 21380078MEM399JPI956

 

Enquiries:

Carclo plc 01924 268040

Frank Doorenbosch - Chief Executive Officer

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTZZGMDVFNGFZM
Date   Source Headline
29th Nov 20071:20 pmRNSDirector/PDMR Shareholding
27th Nov 20077:00 amRNSInterim Results
31st Oct 200710:18 amRNSNotice of Results
3rd Oct 20072:45 pmRNSAdditional Listing
1st Oct 20077:01 amRNSAcquisition & Trading Update
7th Sep 200711:24 amRNSResult of AGM
15th Aug 20077:01 amRNSInterim Management Statement
10th Jul 20072:14 pmRNSDirector/PDMR Shareholding
14th Jun 200712:14 pmRNSDirector/PDMR Shareholding
12th Jun 20077:01 amRNSFinal Results
16th May 20079:59 amRNSNotice of Results
5th Apr 20077:01 amRNSTrading Update
9th Mar 20077:01 amRNSJoint Venture Agreement
9th Mar 20077:01 amRNSJoint Venture Agreement
15th Feb 20072:53 pmRNSDisposal completion
30th Jan 20074:14 pmRNSTotal Voting Rights
21st Dec 200611:12 amRNSTotal Voting Rights
5th Dec 20067:00 amRNSInterim Results
1st Dec 200612:14 pmRNSProperty Disposals
6th Nov 20067:01 amRNSNotice of Results
15th Sep 200612:11 pmRNSDirector/PDMR Shareholding
15th Sep 200612:05 pmRNSDirector/PDMR Shareholding
7th Sep 20067:02 amRNSAGM Statement
27th Jul 20063:11 pmRNSDirector/PDMR Shareholding
14th Jun 20063:00 pmRNSDirector/PDMR Shareholding
12th Jun 20067:00 amRNSFinal Results
18th May 20064:33 pmRNSNotice of Results
12th May 20064:24 pmRNSResult of EGM - Disposal
11th May 200610:58 amRNSResult of EGM
25th Apr 20066:24 pmRNSPosting of Circular
25th Apr 20067:03 amRNSDisposal
4th Apr 20067:01 amRNSTrading Update
9th Feb 200612:01 pmRNSFurther re Board Appointments
3rd Jan 20067:01 amRNSFurther re Board Appointments
7th Dec 200510:11 amRNSDirector/PDMR Shareholding
10th Nov 20053:46 pmRNSNotice of Results
31st Oct 200512:21 pmRNSReduction of Share Premium
10th Oct 200511:53 amRNSTrading Update
4th Oct 20057:00 amRNSRestatement under IFRS
27th Sep 20051:52 pmRNSDirector/PDMR Shareholding
27th Sep 20051:38 pmRNSDirector/PDMR Shareholding
1st Sep 20053:15 pmRNSAGM Statement
29th Jul 20054:37 pmRNSDirector/PDMR Shareholding
29th Jul 200510:08 amRNSDirector/PDMR Shareholding
28th Jul 200512:36 pmRNSDirector/PDMR Shareholding
28th Jul 200511:28 amRNSAcquisition and Placing
23rd Jun 20057:01 amRNSCompletion of Disposal
13th Jun 200511:52 amRNSResult of EGM
13th Jun 20057:01 amRNSFinal Results
26th May 20057:02 amRNSDisposal

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.